Don't miss your opportunity
well positioned to become a leading biotechnology company centered on health and well-being
Entering into the Chronic Pain Market with Psychedelics
Menu
Entering into the Chronic Pain Market with Psychedelics
Shanti has a targeted research pathway to clinical success, with strong proprietary protection under its already submitted patent providing a method for the treatment or prevention of pain.
What are you waiting for?
Just like Cannabis investments of the early 2010s, smart investors are beginning to see the gargantuan upside potential in investments into psychedelics and money has been flowing into start-ups like never before. GWS, through Shanti Therapeutics, has gigantic potential as they are on the forefront of MDMA research in Australia
Shanti plans to conduct clinical research on a fixed-dose combination drug with MDMA as the primary API potential adjuvant analgesic to reduce/ ablate the psychosocial component of pain.
Finding new drug solutions to the puzzle of chronic pain is novel and innovative. Shanti is an early mover with respect to entheogens (psychedelics) being used to modulate the psychosocial component of pain. Concurrent, with the trial being executed in Australia, a pre-IND application to the FDA will be conducted to help identify the best regulatory strategy to a new drug approval.
The hunt is on for the next miracle cure
The team at Shanti in Melbourne is finalizing their clinical protocol with a view to submit for ethics approval in the next few weeks. Nonetheless; preparation has begun for an Australian FIH (First-in-Human) proof of concept trial. This trial will help identify the magnitude of the effect size of MDMA in treating pain which will guide the sample size determination for future pivotal clinical trials.
MDMA has shown promise for PTSD, but the drug alone is unlikely to be a cure. The illegal substance, commonly known as Molly in the 1980’s was known as a college party drug for so long that many still do not believe MDMA paired with psychotherapy improves PTSD pathogenesis. Globally there are approx. 20 significantly funded companies (both listed and unlisted) conducting research and clinical trials into the potential applications (pain management, mental health, PTSD) of Ketamine, Psilocybin, DMT and MDMA and their respective derivatives / compounds.
KaleidoMyco is the story of people, process and production. Together world recognized mycologists and formulists, proprietary science driven IP and formulations, high bioavailability organic compounds, multiple delivery methods plus world-class extraction technologies make KaleidoMyco a leader in the mycology space.
KaleidoMyco is one of the world’s first companies combining hemp-extract (CBD), adaptogens and myco based ingredients to produce world-class wellness products. Their team of scientists are dedicated to driving ground-breaking innovations in the production and delivery of myco derived formulations. The first KaleidoMyco product is combining 50 milligrams of hemp-extract with functional mushrooms to launch a new one-shot wellness beverage utilizing its proprietary extraction techniques.
A short squeeze happens when the perfect market conditions are met and it triggers rapidly rising stock prices.
Analysis of historical trading leads to the conclusion that this junior has been attacked by the naked short selling tactics of the market makers in the US in a hopes to undermine the value of GWS. With the stock price on the rise, its about to explode with forced buy-ins creating a potential windfall for early investors
ADVERTISEMENT DISCLAIMER
This PUBLICATION is an issuer-paid advertisement. This paid advertisement includes a stock profile of Global Wellness Strategies (GWS). To enhance awareness of GWS and its securities, Straight Edge Marketing, Inc. (“Straight Edge”) has a contract for digital marketing and advertising with the issuer with a total budget of approximately two hundred and forty thousand ($240,000.00) USD to cover the costs associated with this and other advertisements for a period of twelve months from May 31, 2022. The website hosting this advertisement, Follow The Ghost, is owned by Global News Publishing, Inc. (“GNP”), an affiliate of Straight Edge. GNP has not been paid to host this advertisement. As a result of this advertisement, GNP may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. Straight Edge will retain any excess sums after all expenses are paid. Global is solely responsible for the contents of this advertisement. As of the date this advertisement is posted to the Global News Publishing website, some or all of Straight Edge, Global, and any of their respective officers, principals, or affiliates (as defined in the Securities Act of 1933, as amended, and Rule 501(b) promulgated thereunder) may hold the securities of GWS’s and may sell those shares during the course of this advertising campaign. This advertisement may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of GWS’s, increased trading volume, and possibly an increased share price of GWS’s securities, which may or may not be temporary and decrease once the advertising campaign has ended.
The information contained on GNP is provided for general informational purposes, as a convenience to the subscribers of GNP. The materials are not a substitute for obtaining professional advice from a qualified person, firm or corporation. Consult the appropriate professional advisor for more complete and current information. GNP is not engaged in rendering any legal or professional services by placing these general informational materials on GNP. GNP and its publishers specifically disclaim any liability, whether based in contract, tort, strict liability or otherwise, for any direct, indirect, incidental, consequential, or special damages arising out of or in any way connected with access to or use of GNP, even if GNP has been advised of the possibility of such damages, including liability in connection with mistakes or omissions in, or delays in transmission of, information to or from the user, interruptions in telecommunications connections to the site or viruses.
GNP makes no representations or warranties about the accuracy or completeness of the information contained on this web site. Any links provided to other server sites are offered as a matter of convenience and in no way are meant to imply that GNP endorses, sponsors, promotes or is affiliated with the owners of or participants in those sites, or endorses any information contained on those sites, unless expressly stated. However, GNP may receive compensation from server sites which may be provided through links. GNP is the copyright owner of all text and graphics contained on this web site, except as otherwise indicated. Other parties’ trademarks and service marks that may be referred to herein are the property of their respective owners. You may print a copy of the information contained herein for your personal use only, but you may not reproduce or distribute the text or graphics to others or substantially copy the information on your own server, or link to this web site, without prior written permission of GNP. Permission to use and reproduce documents and related graphics available from this web site is granted, provided that: (1) the below copyright notice appears in all copies and that both the copyright and this permission notice appear; (2) use and reproduction of documents and related graphics available from this web site is limited to personal, non-commercial use; (3) no documents or related graphics, including logos, available from this web site are modified in any way; and (4) no graphics, including logos, available from this web site are used separate from accompanying text. Use or reproduction for any other purpose is expressly prohibited by law, and may result in civil and criminal penalties. Violators will be prosecuted to the maximum extent possible.
Other than as set forth above, any redistribution of the GNP Newsletters, e-mails, the GNP website or the information contained therein, without the written consent of the publishers of GNP, is strictly prohibited. Copying and/or electronic transmission of the GNP Newsletter, website or content is a violation of copyright law
Global Wellness Strategies is a prospect generator that provides high growth companies with financial, operational, and management assistance in the fast-growing market for wellness consumer products.
Always be the first to know about exiting opportunities from the Ghost. Sign up for alerts and notifications.
Sign up to get tips and insights. Be the first to know about short squeeze alerts & swing trades directly from The Ghost.
